Form 4: Director Rhoads Acquires QuidelOrtho Stock Units

Ann D. Rhoads, a Director at QuidelOrtho Corp, acquired restricted stock units valued at approximately $0, with vesting scheduled through March 2027.

Summary

• Director Ann D. Rhoads acquired 15,532 restricted stock units (RSUs) on June 25, 2026.
• These RSUs were received in lieu of cash payments for retainer and Board of Director service fees.
• The RSUs will vest on June 25, 2027, with specific vesting dates and amounts detailed for future releases.
• Additionally, 3,698 RSUs were converted, and 369 RSUs were received as a premium, all related to deferred compensation.
• The total number of common stock shares beneficially owned by Ms. Rhoads following these transactions is 15,532 (direct ownership).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports on routine equity grants to a director rather than significant financial performance or strategic shifts.

Positives

• Director Ann D. Rhoads has acquired a significant number of restricted stock units, indicating continued commitment and alignment with the company's performance.
• The acquisition of RSUs in lieu of cash payments suggests a strategic decision by the director to defer compensation and invest in the company's future.
• The detailed vesting schedule provides transparency and a clear roadmap for future share ownership.

Negatives

• The reported value of the acquired RSUs is $0, which is typical for equity grants but may be perceived as a lack of immediate financial gain.
• The vesting schedule extends into March 2027, meaning the full benefit of these units will not be realized for some time.

Risks

• The value of the restricted stock units is subject to the future performance of QuidelOrtho Corporation's common stock.
• Vesting is contingent on continued service as a director and adherence to the elected deferral schedule.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on a transaction involving restricted stock units.

Industry Context

StockSavvy.ai notes that the acquisition of restricted stock units by a director is a common practice in the biotechnology and diagnostics industry, reflecting a long-term incentive structure and alignment of management interests with shareholders.

Related Party Transactions

• Ann D. Rhoads, a Director, received restricted stock units in lieu of cash payments for retainer and Board of Director service-related fees under a deferred compensation program.

Stakeholder Impact

• Shareholders: The acquisition of RSUs by a director aligns their interests with long-term company performance, potentially benefiting shareholders.
• Employees: This filing does not directly impact employees, but it reflects standard compensation practices for non-employee directors.
• Management: The RSU grant serves as an incentive for continued service and performance by the director.

Next Steps

• Vesting of restricted stock units according to the specified schedule (June 25, 2027, September 25, 2026, December 25, 2026, and March 25, 2027).
• Release of vested restricted stock units according to the elected deferral schedule.

Key Dates

Keywords

Form 4, SEC Filing, QuidelOrtho Corp, QDEL, Ann D. Rhoads, Director, Restricted Stock Units, RSU, Beneficial Ownership, Equity Grant, Vesting Schedule, Deferred Compensation